- Future Students
- Current Students
- Faculty & Staff
Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
|Title||Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.|
|Publication Type||Journal Article|
|Year of Publication||2003|
|Authors||Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS|
|Journal||The Journal of infectious diseases|
|Date Published||2003 Jun 15|
|Keywords||Animals, Anti-Bacterial Agents, Anti-Infective Agents, Antimalarials, Aza Compounds, Clarithromycin, Disease Models, Animal, Drug Resistance, Bacterial, Drug Therapy, Combination, Ethambutol, Fluoroquinolones, Mefloquine, Mice, Mycobacterium avium Complex, Mycobacterium avium-intracellulare Infection, Quinolines|
Macrolides are the core of effective drug regimens for the treatment of Mycobacterium avium complex (MAC) disease. Mefloquine (MFQ), moxifloxacin (MXF), and ethambutol (EMB), in combination, were evaluated against both clarithromycin-resistant (CLR-R) and CLR-susceptible (CLR-S) MAC; MFQ (40 mg/kg), MXF (100 mg/kg), or EMB (100 mg/kg/day) was given to mice for 4 weeks. MFQ was bactericidal, whereas MXF and EMB were bacteriostatic against both MAC 101 CLR-S and CLR-R. The combination of MFQ and EMB reduced (P<.05, for comparison with controls), and the combination of MFQ and MXF significantly reduced, the load of CLR-R in both the liver and the spleen. Treatment with all 3 drugs was associated with approximately 1-log reduction of CLR-R after 1 week, 2.1-log reduction of CLR-R after 4 weeks, and 2.17-log reduction in MAC/mL blood. Treatment of MAC 101 CLR-S strain had comparable results.
|Alternate Journal||J. Infect. Dis.|